Bacillus anthracis is reported to be naturally resistant to trimethoprim (TMP), a drug that inhibits dihydrofolate reductase (DHFR), a key enzyme in the folate pathway. A microdilution broth assay established that the MIC of TMP for B. anthracis Sterne is >2,048 but <4,096 g/ml. A putative DHFR sequence was amplified from B. anthracis Sterne genomic DNA. The PCR product was cloned into the Invitrogen pCRT7/CT-TOPO vector, followed by transformation into Escherichia coli TOP10F chemically competent cells. Plasmid DNA from a clone showing the correct construct with a thrombin cleavage site attached downstream from the terminus of the cloned PCR product was transformed into E. coli BL21 Star (DE3)pLysS competent cells for expression of the six-histidine-tagged fusion protein and purification on a His-Bind resin column. Functionality of the purified Sterne recombinant DHFR (Sterne rDHFR) was confirmed in an established enzyme assay. The 50% inhibitory concentrations of TMP and methotrexate for the Sterne rDHFR were found to be 77,233 and 12.2 nM, respectively. TMP resistance was observed with E. coli BL21 Star (DE3)pLysS competent cells transformed with the Sterne DHFR gene. Alignment of the amino acid sequence of the Sterne DHFR gene revealed 100% homology with various virulent strains of B. anthracis. These results confirm the natural resistance of B. anthracis to TMP and clarify that the resistance is correlated to a lack of selectivity for the chromosomally encoded gene product. These findings will assist in the development of narrow-spectrum antimicrobial agents for treatment of anthrax.With the increased threat of bioterrorism, it is apparent that the development of new and/or improved antimicrobial agents is a critical and logical response to the hazards that could result from an attack with biological agents. It is important to develop new therapeutics in such a way as to expedite clinical trials and subsequent availability for biodefense. One biological weapon that poses a major threat is the spore-forming gram-positive bacterium Bacillus anthracis, the etiological agent of anthrax.One of the priorities of the National Institute of Allergy and Infectious Diseases division of the National Institutes of Health (NIH) is the design, development, and testing of products specific to category A to C priority pathogens. Bacillus anthracis is on the list of category A priority pathogens. One of the objectives of NIH is to develop narrow-spectrum antimicrobial agents for use in the treatment of anthrax.At this time, three types of antibiotics are approved for treatment of anthrax, ciprofloxacin (a quinolone), tetracyclines (including doxycycline), and penicillins (14). Increasing resistance to quinolones and macrolides can develop in B. anthracis (3), and doxycycline-resistant strains of B. anthacis have been genetically engineered (25). Penicillin-resistant strains have also been identified (4,6,18). Some of these strains were negative for betalactamase production (6), whereas some were not (18). Two antimicrobial a...